Connect with us

News

Former Hollywood Bombshell Raquel Welch Dies at 82

Published

on

Raquel Welch

Raquel Welch, whose appearance in the film “One Million Years B.C.” in a skimpy, furry bikini propelled her to international sex symbol status throughout the 1960s and 1970s, has died. She was 82 years old.

According to her agent, Stephen LaManna of the talent agency Innovative Artists, Welch died early Wednesday after a brief illness.

Despite having only three lines, Welch’s breakthrough came in the campy prehistoric film “One Million Years B.C.” in 1966. She avoided pterodactyls but not public attention while dressed in a brown doeskin bikini.

“I just thought it was a silly dinosaur epic that we’d be able to sweep under the rug one day,” she told The Associated Press in 1981. “Wrong. It turned out that I was the season’s Bo Derek, the lady in the loin cloth about whom everyone exclaimed, ‘My God, what a bod,’ and they expected me to vanish overnight.”

She didn’t, instead playing Lust in Peter Cook and Dudley Moore’s comedy “Bedazzled” in 1967 and a secret agent in the sexy spy spoof “Fathom” that same year.

Raquel Welch Playboy

Raquel Welch’s curves and beauty drew the attention of pop culture, with Playboy crowning her the “most desired woman” of the 1970s despite never being completely naked in the magazine.

She was ranked No. 2 on Men’s Health’s “Hottest Women of All Time” list in 2013. A poster of Welch covers an escape tunnel in the film “The Shawshank Redemption,” the third of three characters Andy Dufresne (Tim Robbins) used after Rita Hayworth and Marilyn Monroe.

Raquel Welch

TV host Rosie O’Donnell, actor Chris Meloni, and writer-director Paul Feig, who worked with Welch on “Sabrina the Teenage Witch” and called her “Kind, funny, and a true superstar whom I was pretty much in love with for most of my childhood,” all took to Twitter to express their condolences. “A true icon has passed away.”

Welch was a singer and dancer in addition to her acting career. She surprised many critics — and received positive feedback — when she replaced a vacationing Lauren Bacall in the Broadway musical “Woman of the Year” in 1981. In 1997, she returned to Broadway with “Victor/Victoria.”

Raquel Welch knew some people did not take her seriously because of her glamorous appearance. “I’m not Penny Marshall or Barbra Streisand,” she said to the Associated Press in 1993. “‘Raquel Welch wants to direct?'” they’ll say. Please give me a break.”‘

Raquel Welch

The Raquel Welch Total Beauty and Fitness Program

Jo-Raquel Tejada was born in Chicago and raised in La Jolla, California. (The Jo in her name comes from her mother, Josephine). When Welch met ex-actor turned press agent Patrick Curtis, she was a divorced mother.

“The irony is that while people thought of me as a sex symbol, I was a single mother of two small children!” “Raquel: Beyond the Cleavage,” her autobiography, says.

Curtis became her manager and second husband, helping shape her into a glam girl with hundreds of magazine covers, films, exercise videos, and books like “The Raquel Welch Total Beauty and Fitness Program.”

Though she would appear in exploitative films, she also surprised many in the industry with strong performances, such as in Richard Lester’s “The Three Musketeers,” for which she received a Golden Globe, and in “Wild Party,” opposite James Coco. She was also nominated for a Golden Globe in 1988 for the television film “Right to Die.” In an episode of “Seinfeld,” she played herself and mocked divas, famously attacking Elaine and rattling Kramer.

Raquel Welch was married and divorced four times and is survived by two children, Damon Welch and Tahnee Welch, who both became actors, including a role in 1985’s “Cocoon.”

Geoff Thomas is a seasoned staff writer at VORNews, a reputable online publication. With his sharp writing skills and deep understanding of SEO, he consistently delivers high-quality, engaging content that resonates with readers. Thomas' articles are well-researched, informative, and written in a clear, concise style that keeps audiences hooked. His ability to craft compelling narratives while seamlessly incorporating relevant keywords has made him a valuable asset to the VORNews team.

Continue Reading

News

Katie Ledecky Hopes For Clean Races At Paris Olympics In The Aftermath Of The Chinese Doping Scandal

Published

on

ledecky

PARIS — Katie Ledecky is looking for clean Olympic races. On Wednesday, Hope had pretty much reached her limit.

The American swimmer hopes to add to her six gold medals as she competes in the 400, 800, and 1,500 meters at the Paris Games. Her program starts with the heavy 400 on Saturday, featuring Ariarne Titmus and Summer McIntosh.

ledecky

Katie Ledecky | ESPN Image

Katie Ledecky Hopes For Clean Races At Paris Olympics In The Aftermath Of The Chinese Doping Scandal

The 27-year-old Katie is competing in her fourth Summer Olympics, but the first since a doping scandal involving almost two dozen Chinese swimmers who tested positive for a banned chemical before the Tokyo Games — yet were permitted to compete with no consequences. The controversy has raised serious worries regarding the effectiveness of anti-doping initiatives.

ledecky

Katie Ledecky | Vogue Image

“I hope everyone here is going to be competing clean this week,” Ledecky claimed. “But what truly counts is, were they training cleanly? Hopefully this has been the case. Hopefully, there has been worldwide testing.”

The International Olympic Committee has expressed concern over the ongoing US investigation into possible doping by Chinese swimmers. While awarding the 2034 Winter Olympics to Salt Lake City on Wednesday, the IOC urged Utah officials to do whatever they could to stop the FBI investigation.

“I think everyone’s heard what the athletes think,” Katie added. “They seek transparency. They want more answers to the remaining questions. At this point, we are here to race. We are going to race whoever is in the lane next to us.

“We are not paid to conduct the tests, so we trust those who follow their regulations. That applies both today and in the future.

 

ledecky

Katie Ledecky | ESPN Image

Katie Ledecky Hopes For Clean Races At Paris Olympics In The Aftermath Of The Chinese Doping Scandal

SOURCE | AP

Continue Reading

News

London Heatwave Alert: High Temperatures Set to Soar to 29C Next Week

Published

on

London Heatwave Alert High Temperatures Set to Soar to 29C Next Week

As the summer holidays begin, London may experience an official heatwave with temperatures reaching up to 29 degrees Celsius.

The Met Office predicts a long period of sunny and dry weather for London after a soggy spring and summer.

After a cloudy day on Saturday, temperatures are expected to reach 27C on Sunday, with lots of sunlight.

On Monday and Tuesday, temperatures are forecast to peak at 29 degrees Celsius. Monday is forecast to offer more sunlight, while Tuesday may see some gloomy weather.

VOR News

Temperatures are expected to remain in the high 20s next week, with lows of approximately 18C.

According to the Met Office, a heatwave is “an extended period of hot weather relative to the expected conditions of the area at that time of year, which may be accompanied by high humidity.”

In the United Kingdom, a heatwave is proclaimed when daily temperatures meet or surpass a certain level for at least three consecutive days.

In London, the heatwave threshold is 28 degrees Celsius.

The Met Office reported that the UK is experiencing hotter and wetter weather on average due to climate change.

The UK experienced its warmest May and April on record this year, despite damp and dismal conditions in many areas.

According to the Met Office’s State Of The UK Climate 2023 report published on Thursday, the UK experienced historic levels of extreme weather last year.

In the United Kingdom, 2023 was the second warmest year on record, bringing storms, flooding, strong heatwaves, and rising sea levels; only 2022 was warmer.

It was 0.8°C higher than the average from 1991 to 2020, and 1.66°C higher than the 1961 to 1990 average.

However, 2023 will be a “cool year” in comparison to 2100, based on the planet’s warming trajectory.

The government’s plan to adapt to the hazards presented by climate change is currently being challenged in the High Court by campaigners who allege the Tory administration’s July 2023 National Adaptation Programme (NAP) fails to adequately address 61 concerns.

Source: The Standard

Continue Reading

News

Novo Nordisk’s Wegovy is a Heart-Risk-Reducing Product.

Published

on

Wegovy
Hollie Adams | Reuters

(VOR News) – The European Union’s medical regulator has granted approval to Wegovy, a blockbuster weight loss treatment manufactured by Novo Nordisk, in order to expand its application to include the reduction of major heart events in overweight or obese adults.

In order to expand the scope of the medication’s applicability, this authorisation was granted. The purpose of obtaining this approval was to broaden the medicine’s application.

The Danish pharmaceutical company announced on Thursday that the European Medical Agency has formulated a “positive opinion” regarding the label’s expansion.

The agency made this determination after conducting a comprehensive examination of the results of a SELECT study that was subjected to rigorous monitoring. Other applications of the substance are facilitated by this conclusion.

The SELECT experiment, which was financed by Novo Nordisk and published in August 2023.

Wegovy and Ozempic contain semaglutide as the active ingredient.

Reduced the risk of major cardiovascular events by twenty percent when compared to a placebo. The researchers arrived at this conclusion. This realisation was the outcome of the researchers’ investigation.

The notion that the European Medicines Agency label for Wegovy should be amended is a significant step forward for patients who are coping with cardiovascular disease and obesity, according to Martin Holst Lange, executive vice president and director of development at Novo Nordisk.

The company’s statement, which was disclosed, indicated that the recommendation to update the label is a substantial advancement.

It is evident that Wegovy has the potential to save lives by reducing the likelihood of significant adverse cardiovascular events, as evidenced by the findings of the SELECT research. An additional benefit of participating in this exercise is that it helps individuals effectively manage their weight, which is a benefit in and of itself.

The company also stated that the label update incorporates data from the SELECT trial, which showed a 15% reduction in the risk of death from cardiovascular causes and a 19% reduction in the risk of death from any cause when compared to situations in which a placebo was used in conjunction with the product.

The SELECT trial was conducted in the United States, according to the company. Furthermore, the organisation disclosed that the SELECT investigation was conducted in the United States of America.

It is anticipated that the label amendment will be implemented within the next month, as per the statement issued by Novo Nordisk.

Wegovy has also been approved for use in the United States.

Similarly, the UK medical regulator has taken similar actions. The United Kingdom on Tuesday granted its clearance for the use of Wegovy to reduce the risk of significant cardiac difficulties or strokes in adults who are overweight or obese, such as heart attacks or strokes.

The Food and Drug Administration of the United States of America granted sanction for the medicine to be used in specific applications during the month of March.

This resulted in a rise in the number of distinct applications for the highly popular treatment, which coincides with the sector’s increasing level of competition.

On Thursday, Roche, a global pharmaceutical company with its headquarters in Switzerland, announced that its Wegovy competitor weight reduction tablets will be incorporated into a collection of pharmaceuticals designed to mitigate the adverse effects of obesity.

The pharmaceutical collection will encompass a diverse selection of weight loss medications.

The company’s Chief Executive Officer, Thomas Schinecker, conveyed his satisfaction with the exceptional early-stage trial results of the two potential weight-reduction pharmaceuticals that the company is currently developing. In addition, he asserted that these medications demonstrated the “best in disease potential.”

In making this assertion, Schinecker was alluding to the fact that the medications exhibited the “best in disease potential.” He also stated that they will be a part of a more comprehensive portfolio that is intended to set the Swiss company apart from its competitors in the growing obesity therapy market.

This adds insult to injury. This strategy will be implemented in order to distinguish the Swiss company from other businesses in the market.

SOURCE: CNBC

SEE ALSO:

A Strong U.S. GDP Report Boosts Oil, but Asia’s Economic Woes Limit Gains.

Surge in Covid Cases in Greece: Tourists Issued FLiRT Variant Warning

Business Owners Blame the Government’s Economic Incompetence for Rising Inflation.

 

Continue Reading

Trending